Correction to: Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations

Correction to: BMC Cancer (2018) 18:264

https://doi.org/10.1186/s12885-018-4050-1

Following publication of the original article [1], the authors reported errors in Fig. 3, Fig. 14a, Fig. 18, Fig. 19b, Additional file 3 and Additional file 7. The title of Additional file 9 contains a typing error and is correctly given below.

Fig. 3.

Most active compound (IC₅₀ = 0.2) mapped to all the features

Fig. 14.

a Molecular interaction between the reference- protein (purple). Green dotted lines indicate the hydrogen bonds. The residues are represented in orange stick model

Fig. 18.

Binding mode assessment of compounds. The co-crystal is represented in gray, reference is denoted in green and the Hit in orange. All the three follow the same pattern

Fig. 19.

b Intermolecular interactions between the ligand and the protein. Green dotted lines represent the hydrogen bonds. The protein residues are indicated in cyan

The following typing errors have been identified:

Page no	Column/paragraph	line	Present word	Change to
1	Abstract/results	2	of	above
2	1/2	2	Cyclic	Cyclin
2	2/1	3	VEGFR	VEGFR-2
12	2/1	3	prognosis	progression
12	2/1	10	form	from
19	Above conclusions	4	Cyc919	Cys919
10	2/1	13	20 ps	20 ns
10	2/1	15	25 ps	25 ns
13	2/1	6	four	five
Table 5/ reference	van der Waals interactions	–	asn900leu1044	Asn900, Ile1044
Fig 10	–	–	30 ps	30 ns
Fig 16	–	–	refrence	reference

Further to this, in Table 1, HyP is incorrectly represented as HyB and Hy-Ali as HyAli/HY-Ali. The corrected Table 1 can be found here.

Table 1

Hypo no	Total costa	Cost difference	RMSDb	Correlation	Featuresc	Max fit
Hypo1	111.95	71.22	0.7	0.97	Hy-Ali, 2HyP,RA	11.4
Hypo 2	113.31	69.86	0.7	0.96	Hy-Ali, 2HyP,RA	11.5
Hypo 3	116.45	66.71	0.8	0.95	Hy-Ali,HyP,RA,HBA	11.9
Hypo 4	116.47	66.69	1.0	0.94	HBA, HBD 2HyP	10.7
Hypo 5	117.11	66.05	0.9	0.94	Hy-Ali,HyP,RA,HBA	11.5
Hypo 6	119.51	63.65	1.0	0.93	HBA,HBD,2HyP	11.26
Hypo 7	119.52	63.65	0.9	0.95	HBA,2HyP,RA	12.65
Hypo 8	119.82	63.35	0.9	0.94	HBA,Hy-Ali,HBD,RA	12.33
Hypo 9	119.94	63.23	1.2	0.91	HBA,Hy-Ali,2HyP, RA	11.98
Hypo10	120.52	62.65	1.1	0.91	HBA,HBD, Hy-Ali	7.8

These corrections do not alter the context of the manuscript.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s12885-019-6378-6.